Related Experiment Video
Updated: Oct 22, 2025
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
16.1K
Melanoma: Staging and Follow-Up
Chryssoula Papageorgiou1, Zoe Apalla1, Sofia-Magdalini Manoli2
1Second Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
Dermatology Practical & Conceptual
|August 27, 2021
Summary
Accurate melanoma staging is crucial for prognosis and treatment decisions. Lifelong patient monitoring is essential for detecting recurrence or new melanomas, with intensified follow-up in the first five years.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Cancer staging determines the extent and location of cancer spread, guiding prognosis and treatment.
- The current melanoma staging system relies on the 8th edition of the American Joint Committee on Cancer (AJCC) TNM classification.
- Key factors in melanoma staging include tumor thickness, ulceration, lymph node involvement, and metastasis.
Purpose of the Study:
- To emphasize the importance of accurate melanoma staging for prognostic estimation and treatment planning.
- To highlight the necessity of a thorough medical workup and continuous patient monitoring after melanoma diagnosis.
- To address the lack of a universally adopted follow-up strategy and the need for future research.
Main Methods:
- Utilizing the 8th edition of the AJCC TNM classification for melanoma staging.
- Incorporating clinical and pathological staging criteria.
- Considering factors such as Breslow thickness, ulceration, lymph node status, and metastasis.
Main Results:
- Accurate staging provides the most reliable prognostic estimation.
- Treatment choices and follow-up strategies are significantly influenced by the determined tumor stage.
- Continuous, lifelong patient monitoring is fundamental for early detection of relapse or secondary melanomas.
Conclusions:
- Proper melanoma staging is critical for accurate prognosis and informed treatment decisions.
- A personalized follow-up approach, considering patient risk factors and recent therapies, is recommended.
- Lifelong surveillance is necessary due to the risk of recurrence and new primary melanomas, with higher intensity follow-up recommended in the initial five years.
